Publications
-
- Conference presentation
- [AAIC 2026] A Novel GPX4 Positive Allosteric Modulator Ameliorates Cognitive Impairment by Inhibiting Ferroptosis and Neuroinflammation
-
- Conference presentation
- [AAIC 2026] Therapeutic Evaluation of DA-7503, a Tau Aggregation Inhibitor, P3-01 # 4668 Alone and in Combination with Lecanemab in Tauopathy & AD Models
-
- Conference presentation
- [ADA 2026] Synergistic Hepatoprotective and Weight Loss Effects of Vanoglipel and Resmetirom Combination Therapy in a Diet-Induced Obese and Biopsy-Confirmed Mouse Model of MASH
-
- Conference presentation
- [ADA 2026] Synergistic Effects of Vanoglipeland Metformin on Glycemic Control and Body Weight Reduction in a Diet-Induced Obese Mouse Model
-
- Conference presentation
- [ADA 2026] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DA-1726, an Oxyntomodulin Analogue: Phase 1 Higher-Dose Cohort Results
-
- Conference presentation
- [AACR 2026] Overcoming target heterogeneity in gastric cancer with an eKiHengineered CLDN18.2×HER2 bispecific ADC
-
- Conference presentation
- [AACR 2026] Overcoming EMT-associated tumor progression in solid tumor with an eKiH-engineered HER2×AXL bispecific ADC
-
- Conference presentation
- [AACR 2026] NECTIN4×PD-L1 bispecific antibody-drug conjugate integrating checkpoint blockade and targeted cytotoxicity for urothelial carcinoma and head and neck squamous cell carcinoma
-
- Conference presentation
- [AACR 2026] Integrated platform for developing bispecific antibody drug conjugates (bsADC) for optimal targeting of heterogenous solid tumors
-
- Conference presentation
- [AACR 2026] DA-3501 (AT-211): Evaluation of immune-mediated antitumor activity and combination immunotherapy potential of a site-specific CLDN18.2-targeting antibody-drug conjugate (ADC)